The clinical expertise of a Chief Medical Officer, available 1–2 days per week. Governance, regulatory affairs, patient safety, and medical strategy — for the organisations that need it most but can't yet justify a full-time appointment.
The fractional CMO model is ideal where clinical leadership is absent or under-resourced. If you have one medic or none and need senior clinical input, this is designed for you.
Start-ups and scale-ups needing clinical credibility — for investors, DCB0129/DTAC compliance, and building trust with NHS buyers.
Device companies working towards UKCA/CE marking that need a clinical evaluation lead, post-market surveillance, and regulatory strategy.
Pre-Series A to Series B companies needing their first medical affairs function, pharmacovigilance, or clinical trial oversight.
Independent GP networks, aesthetics groups, cosmetic surgery chains, and specialist clinics that need CQC governance and a named medical lead.
Care home groups, homecare organisations, and supported living providers regulated by CQC that lack an in-house medical director.
Employers and occupational health providers building a structured health and wellbeing programme needing senior clinical oversight.
Supplement brands, functional food companies, and wellness products needing medical affairs and health claims substantiation.
Sports medicine clinics, elite performance centres, and aesthetic medicine groups requiring clinical governance and medical director-level oversight.
Insurtech and health insurance products needing clinical governance, and legal practices requiring a senior clinical expert witness or medical advisor.
A fractional Chief Medical Officer delivers the full breadth of a CMO function — governance, regulatory, safety, strategy — at a scale and cost appropriate to your organisation's stage.
Build and embed a clinical governance framework — from policy architecture and clinical audit to serious incident review. Prepare your organisation for CQC inspection and ensure you are operating safely and compliantly.
Navigate the UK regulatory landscape with confidence. Develop your MHRA submission strategy, manage clinical evaluation reports for UKCA/CE marking, or prepare for a NICE submission or health technology assessment.
Design and implement a robust patient safety framework, including Duty of Candour, serious incident reporting under PSIRF, and pharmacovigilance systems for drug and device companies.
Build the medical affairs function your organisation needs — publications strategy, KOL engagement, medical education, scientific advisory boards, and evidence generation planning.
Act as Clinical Safety Officer under DCB0129, lead the Digital Technology Assessment Criteria (DTAC) process, and provide clinical oversight for AI/ML-enabled digital health products seeking NHS adoption.
Provide clinical credibility for investor presentations, due diligence processes, and funding applications. Experienced supporting Series A–C rounds, NHS procurement bids, and grant applications.
Design clinical evaluation strategies, oversee evidence generation programmes, advise on study design and site selection, and manage CRO relationships for early-phase and observational research.
Act as the named Medical Director, Responsible Officer, or Designated Prescribing Practitioner as required by CQC, NHS England, or your regulator — providing the clinical leadership sign-off your registration requires.
Provide senior clinical expert opinion in medico-legal contexts — from initial case review and opinion letters through to CPR Part 35-compliant expert reports and occasional court attendance.
From first contact to a working fractional CMO engagement typically takes 10–14 days.
A 30-minute confidential call to understand your organisation, your clinical risks, and what you need from senior medical leadership.
A clear written proposal — engagement level, working rhythm, deliverables, and transparent pricing — returned within 48 hours of the discovery call.
Contracts signed digitally. Structured onboarding session with your leadership team, followed by an initial clinical risk and governance assessment.
Regular working sessions, board attendance, async availability, and quarterly reviews. Real clinical leadership, not just advice on paper.
Three engagement levels matched to the complexity and scale of your clinical leadership needs. All engagements are a minimum of six months.
For organisations with defined, bounded clinical needs — governance, a specific regulatory workstream, or CQC preparation — that don't yet require a full CMO presence.
The full fractional CMO model — spanning governance, regulatory, patient safety, and medical strategy. The right level for most organisations appointing their first medical leader.
Senior clinical advisory for organisations that need strategic input, investor or regulatory support, and a credible medical voice at board level — without operational clinical leadership.
All engagements are structured as monthly retainers, billed in advance. Pricing is discussed openly during the discovery call — there are no hidden costs or variable billing.
These are the scenarios where a fractional CMO engagement delivers the most impact.
A Series A digital health company needs clinical credibility for their NHS procurement bid and DCB0129 compliance. No in-house medic exists. They need a named Clinical Safety Officer and someone who can represent them in clinical discussions with NHS buyers.
A diagnostics company needs to complete their Clinical Evaluation Report (CER) and post-market surveillance plan for UKCA marking. They lack in-house clinical expertise and need a senior clinician to own the process and liaise with their Notified Body.
A group of aesthetic and cosmetic surgery clinics is preparing for a CQC inspection. Governance frameworks are incomplete, incident reporting is inconsistent, and there is no named Medical Director. An imminent CQC visit has heightened the urgency.
A pre-Series B biotech company is approaching first-in-human studies. They need a pharmacovigilance system, a qualified safety officer function, and a medical affairs strategy ahead of their next funding round.
A growth equity investor is conducting due diligence on a health technology acquisition. They need independent senior clinical input to assess clinical risk, regulatory status, and the credibility of the target's medical claims.
A group of care homes is CQC-registered and requires a named Medical Director. Their previous medical lead retired and they need a qualified replacement who can provide governance oversight and clinical leadership across multiple sites.
No obligation. A confidential conversation to understand your clinical leadership needs and whether a fractional CMO engagement is the right fit.
The discovery call works best when you come prepared with:
Calls are conducted via Zoom or Teams. A calendar invite with joining details is sent automatically on booking.
Prefer to write first? Complete the form and we'll respond within one business day. All enquiries are treated with complete confidentiality.
🔒 Confidentiality Guarantee
Your details are kept strictly confidential and never shared with third parties. An NDA is available on request prior to any substantive discussion.
Thank you — we'll be in touch within one business day.
In the meantime, feel free to book a discovery call directly.
In-depth articles on clinical governance, regulatory affairs, and medical leadership — written for the CEOs, founders, and board members of growing healthcare organisations.
The role is relatively new, often misunderstood, and still largely absent from search results — which is precisely why it represents such an opportunity for growing healthcare organisations.
They sound similar and are sometimes used interchangeably — but fractional and interim Chief Medical Officers are fundamentally different models with different costs, timelines, and outputs.
Pricing for fractional CMO services in the UK is rarely published openly. This article changes that — with a clear breakdown of what you should expect to pay and what drives the cost.
Many healthcare founders ask the same question at the wrong time — usually when a CQC inspector, investor, or regulator has already raised it for them. Here's how to get ahead of it.